SIGA TECHNOLOGIES INCSIGAEarnings & Financial Report
SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
Revenue
$81.1M
Gross Profit
$55.6M
Operating Profit
$45.7M
Net Profit
$35.5M
Gross Margin
68.5%
Operating Margin
56.3%
Net Margin
43.7%
YoY Growth
271.9%
EPS
$0.49
SIGA TECHNOLOGIES INC Q2 FY2025 Financial Summary
SIGA TECHNOLOGIES INC reported revenue of $81.1M (up 271.9% YoY) for Q2 FY2025, with a net profit of $35.5M (up 1836.2% YoY) (43.7% margin). Cost of goods sold was $25.6M, operating expenses totaled $9.9M.
Key Financial Metrics
| Total Revenue | $81.1M |
|---|---|
| Net Profit | $35.5M |
| Gross Margin | 68.5% |
| Operating Margin | 56.3% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
SIGA TECHNOLOGIES INC Q2 FY2025 revenue of $81.1M breaks down across 2 segments, led by Product Sales And Supportive Services at $79.1M (97.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product Sales And Supportive Services | $79.1M | 97.5% |
| Research And Development | $2.0M | 2.5% |
SIGA TECHNOLOGIES INC Annual Revenue by Year
SIGA TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $94.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $94.6M |
| 2024 | $138.7M |
| 2023 | $139.9M |
| 2022 | $110.8M |
SIGA TECHNOLOGIES INC Quarterly Revenue & Net Profit History
SIGA TECHNOLOGIES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.8M | -95.3% | N/A | N/A |
| Q3 FY2025 | $2.6M | -73.8% | $-6.4M | -243.0% |
| Q2 FY2025 | $81.1M | +271.9% | $35.5M | 43.7% |
| Q1 FY2025 | $7.0M | -72.3% | $-408.2K | -5.8% |
| Q4 FY2024 | $81.5M | -30.1% | $45.8M | 56.2% |
| Q3 FY2024 | $10.0M | +8.4% | $1.3M | 13.4% |
| Q2 FY2024 | $21.8M | +271.0% | $1.8M | 8.4% |
| Q1 FY2024 | $25.4M | +205.5% | $10.3M | 40.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.4M | $21.8M | $10.0M | $81.5M | $7.0M | $81.1M | $2.6M | $3.8M |
| YoY Growth | 205.5% | 271.0% | 8.4% | -30.1% | -72.3% | 271.9% | -73.8% | -95.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $243.1M | $192.7M | $195.4M | $244.3M | $247.1M | $235.3M | $231.6M | $219.5M |
| Liabilities | $78.2M | $25.1M | $25.9M | $28.5M | $30.9M | $26.0M | $28.1M | $20.6M |
| Equity | $165.0M | $167.6M | $169.4M | $215.8M | $216.1M | $209.3M | $203.5M | $198.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.1M | $6.0M | $-7.4M | $56.3M | $7.1M | $63.1M | $-9.8M | $43.5M |